ReadyRx Customer Support Email: [email protected] Website: www.readyrx.com Disclaimers and Legal Notices Medical Disclaimer This publication is intended for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations
Annals of the Rheumatic Diseases, 74(3), 480-489
In the first head-to-head trial, SURMOUNT-5 (2025), tirzepatide beat semaglutide directly 20.2% versus 13.7% over 72 weeks (New England Journal of Medicine, 2025)
This analysis reinforces that ongoing pharmacotherapy and NOT short-term courses is critical for sustaining both weight loss and its cardiometabolic benefits
There are simple and effective strength exercises which are essential for sustainable results. Originally developed for the treatment of type 2 diabetes, GLP-1 (glucagon-like peptide 1) receptor agonists mimic a natural hormone to suppress appetite, promote weight loss, and reduce cardiovascular risk